|
2022 Journal Article Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort studyJiang, Yingying, Shi, Yue, Liu, Yiling, Wang, Zihan, Ma, Yuxin, Shi, Xinhong, Lu, Lin, Wang, Zhitong, Li, Hang, Zhang, Yushu, Liu, Caolu, Zhang, Shaorui, Zhong, Zhihao, Lu, Jianwei, Shi, Meiqi, Shen, Bo, Zhou, Guoren, Yin, Rong, Galetta, Domenico, Grenda, Anna, Romero, Atocha, Hughes, Brett G. M., Chen, Cheng, Wang, Xiaohua and Feng, Jifeng (2022). Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. Translational Lung Cancer Research, 11 (12), 2521-2538. doi: 10.21037/tlcr-22-857 |
|
2022 Conference Publication High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy responseKulasinghe, Arutha, Sadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Church, Sarah, Schneider, Fabian, Thaagard, Jeppe, Mansfield, James, O’byrne, Kenneth, Davis, Melissa and Hughes, Brett (2022). High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response. SITC 37th Annual Meeting (SITC 2022), Boston, MA United States, 8–12 November 2022. London, United Kingdom: BMJ Group. doi: 10.1136/jitc-2022-sitc2022.0117 |
|
2022 Conference Publication The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC)Turner, Cassie L., Prasetio, Tito E., O'Berine, Shannon, Anderson, Georgina, Hughes, Brett G. M., Vignarajah, Dinesh, Castelli, Joanne, Lwin, Zarnie, Houston, Kathleen and Chan, Bryan A. (2022). The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC). HOBOKEN: WILEY. |
|
2022 Journal Article Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 StudyHarrington, Kevin J., Burtness, Barbara, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Lin, Jianxin, Gumuscu, Burak, Swaby, Ramona F. and Rischin, Danny (2022). Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 Study. Journal of Clinical Oncology, 41 (4), 790-802. doi: 10.1200/jco.21.02508 |
|
2022 Journal Article Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinomaGross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo B., Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G.M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Kaufman, Howard L., Seebach, Frank, Lowy, Israel, Yoo, Suk-Young, Mathias, Melissa, Fenech, Keilah, Han, Hyunsil, Fury, Matthew G. and Rischin, Danny (2022). Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. New England Journal of Medicine, 387 (17), 1557-1568. doi: 10.1056/nejmoa2209813 |
|
2022 Journal Article Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic reviewEdwards, Anna, Hughes, Brett G M, Brown, Teresa and Bauer, Judith (2022). Prevalence and impact of computed tomography-defined sarcopenia on survival in patients with human papillomavirus-positive oropharyngeal cancer: a systematic review. Advances in Nutrition, 13 (6), 2433-2444. doi: 10.1093/advances/nmac076 |
|
2022 Journal Article Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive scoreBurtness, Barbara, Rischin, Danny, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Ge, Joy, Swaby, Ramona F., Gumuscu, Burak and Harrington, Kevin (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. Journal of Clinical Oncology, 40 (21), 2321-2332. doi: 10.1200/jco.21.02198 |
|
2022 Journal Article Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancerKapeleris, Joanna, Bark, Juliana Müller, Ranjit, Shanon, Irwin, Darryl, Hartel, Gunter, Warkiani, Majid Ebrahimi, Leo, Paul, O’Leary, Connor, Ladwa, Rahul, O'Byrne, Kenneth, Hughes, Brett G.M. and Punyadeera, Chamindie (2022). Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 8 (7) e09971, 1-9. doi: 10.1016/j.heliyon.2022.e09971 |
|
2022 Journal Article Application of circulating tumour cells to predict response to treatment in head and neck cancerZhang, Xi, Ekanayake Weeramange, Chameera, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid Ebrahimi, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz and Punyadeera, Chamindie (2022). Application of circulating tumour cells to predict response to treatment in head and neck cancer. Cellular Oncology, 45 (4), 1-13. doi: 10.1007/s13402-022-00681-w |
|
2022 Journal Article A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancerCapdevila, Jaume, Klochikhin, Arkadiy, Leboulleux, Sophie, Isaev, Pavel, Badiu, Corin, Robinson, Bruce, Hughes, Brett G.M., Keam, Bhumsuk, Parnis, Francis, Elisei, Rossella, Gajate, Pablo, Gan, Hui K., Kapiteijn, Ellen, Locati, Laura, Mangeshkar, Milan, Faoro, Leonardo, Krajewska, Jolanta and Jarzab, Barbara (2022). A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer. Thyroid, 32 (5), 515-524. doi: 10.1089/thy.2022.0027 |
|
2022 Journal Article Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell CarcinomasSadeghirad, Habib, Monkman, James, Mehdi, Ahmed M., Ladwa, Rahul, O’Byrne, Ken, Hughes, Brett G. M. and Kulasinghe, Arutha (2022). Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. Frontiers in Immunology, 13 895513, 1-11. doi: 10.3389/fimmu.2022.895513 |
|
2022 Journal Article Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, René Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan and Burtness, Barbara (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128 105815, 1-12. doi: 10.1016/j.oraloncology.2022.105815 |
|
2022 Journal Article The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic reviewEdwards, Anna, Brown, Teresa, Hughes, Brett G. M. and Bauer, Judy (2022). The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review. Supportive Care in Cancer, 30 (9), 7191-7204. doi: 10.1007/s00520-022-07056-9 |
|
2022 Journal Article A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancerBrose, Marcia S., Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K., Leboulleux, Sophie, Binder, Terri A., Dutcus, Corina, Xie, Ran and Taylor, Matthew H. (2022). A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 107 (3), 776-787. doi: 10.1210/clinem/dgab731 |
|
2022 Journal Article Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatmentAhern, Elizabeth, Brown, Teresa E, Campbell, Louise, Hughes, Brett G. M., Banks, Merrilyn D., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2022). Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. British Journal of Nutrition, 129 (3) PII S0007114522000435, 1-25. doi: 10.1017/S0007114522000435 |
|
2022 Journal Article Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialPeters, S., Pujol, J. L., Dafni, U., Dómine, M., Popat, S., Reck, M., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., Gervais, R., López Vivanco, G., Madelaine, J., Mazieres, J., Faehling, M., Griesinger, F., Majem, M., González Larriba, J. L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Stahel, R. A., Le Pechoux, C., De Ruysscher, D. ... Califano, R. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology, 33 (1), 67-79. doi: 10.1016/j.annonc.2021.09.011 |
|
2022 Journal Article Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialKok, Peey Sei, Forde, Patrick M., Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O'Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M., Stockler, Martin and Nowak, Anna K. (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12 (1) e057663, e057663. doi: 10.1136/bmjopen-2021-057663 |
|
2022 Journal Article Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))Hughes, B. G.M., Munoz-Couselo, E., Mortier, L., Bratland, , Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J. J. (2022). Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). Annals of Oncology, 33 (8), 853-853. doi: 10.1016/j.annonc.2022.05.517 |
|
2022 Journal Article Understanding the tumor microenvironment in head and neck squamous cell carcinomaRad, Habib Sadeghi, Shiravand, Yavar, Radfar, Payar, Ladwa, Rahul, Perry, Chris, Han, Xiaoyuan, Warkiani, Majid Ebrahimi, Adams, Mark N., Hughes, Brett G.M., O'Byrne, Ken and Kulasinghe, Arutha (2022). Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical & Translational Immunology, 11 (6) e1397, e1397. doi: 10.1002/cti2.1397 |
|
2021 Journal Article Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapyBlake, Claire, Edwards, Anna, Treleaven, Elise, Brown, Teresa, Hughes, Brett, Lin, Charles, Kenny, Lizbeth, Banks, Merrilyn and Bauer, Judy (2021). Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy. Nutrition and Dietetics, 79 (2), 206-216. doi: 10.1111/1747-0080.12714 |
